Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Executive Summary
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.
You may also be interested in...
Novo Nordisk Pays $1.80bn To Buy Emisphere
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.